newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Moneycontrol
Zaynich, a combination of Zidebactam and Cefepime, has been cleared for the treatment of complicated urinary tract infections.
The FDA approved Wockhardt’s Zaynich for complicated urinary tract infections in adults.
KEY POINTS
Zaynich is effective against Gram-negative bacteremia, including extensively drug-resistant (XDR) pathogens.
Wockhardt also received approval from India's CDSCO to import and market Zaynich domestically.
The pivotal ENHANCE-1 phase 3 trial showed Zaynich's efficacy against meropenem in cUTI patients.
The Clinical and Laboratory Standards Institute assigned an investigational susceptible breakpoint of 64 mg/L to Cefepime/Zidebactam.
The US Food and Drug Administration (FDA), on Saturday, approved Wockhardt’s antibiotic Zaynich for the treatment of complicated urinary tract infections (cUTIs) in adults caused by designated susceptible microorganisms, the company said on Thursday.
Zaynich, a combination of Zidebactam and Cefepime, has been cleared for the treatment of complicated urinary tract infections, including kidney infections known as pyelonephritis, in adult patients. The approval also covers cases accompanied by Gram-negative bacteremia, a serious bloodstream infection caused by bacteria.
Earlier on Friday, Wockhardt Ltd said it has also received approval from India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), for the import and marketing of the indigenously discovered and developed antibiotic in the country.
“The approval is for the treatment of adult patients (18 years and above) with complicated urinary tract infections (cUTI), including pyelonephritis, as well as cases with concurrent Gram-negative bacteremia,” the company said in a regulatory filing.
According to Wockhardt, the approvals were backed by data from the pivotal ENHANCE-1 study, a multinational, randomised, double-blind Phase 3 clinical trial that evaluated the efficacy and safety of Zaynich against meropenem in patients suffering from cUTI, including pyelonephritis.
The company said the drug demonstrated efficacy against difficult-to-treat Gram-negative bacterial infections, including extensively drug-resistant (XDR) pathogens.
“In recognition of its broad-spectrum potential, the Clinical and Laboratory Standards Institute has assigned Cefepime/Zidebactam an investigational susceptible breakpoint of 64 mg/L,” Wockhardt said, adding that the designation supports the drug’s potential use against clinically significant XDR Gram-negative pathogens in critically ill patients.
Zaynich combines Cefepime, a fourth-generation cephalosporin antibiotic, with Zidebactam, a novel beta-lactam enhancer developed by Wockhardt.